AR054865A1 - METAL COMPLEXES WITH CONTENT OF PERFLUOROALQUILO, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE - Google Patents
METAL COMPLEXES WITH CONTENT OF PERFLUOROALQUILO, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USEInfo
- Publication number
- AR054865A1 AR054865A1 ARP060103020A ARP060103020A AR054865A1 AR 054865 A1 AR054865 A1 AR 054865A1 AR P060103020 A ARP060103020 A AR P060103020A AR P060103020 A ARP060103020 A AR P060103020A AR 054865 A1 AR054865 A1 AR 054865A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- site
- omega
- union
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Complejos con contenido de perfluoroalquilo con estructura de ligador con nitrogeno de la formula general (1), en donde: R representa un radical mono- u oligosacárido unido a través de 1-OH, en este caso Q tiene el significado de un grupo seleccionado de. delta-CO-(CH2)n''-épsilon; delta-NH-(CH2)n''-épsilon; delta-(CH2)m-épsilon; en donde n'' es un numero entero de 1 y 5, y m es un numero entero de 1 y 6; y en donde delta indica el sitio de union con el ligador L y épsilon indica el sitio de union con el radical R; o R tiene uno de los siguientes significados, entonces Q tiene el significado de un enlace directo: R significa un radical polar seleccionado de: los complejos K de las formulas generales (2) a V, en donde R1 significa aquí un átomo de hidrogeno o un equivalente de ion metálico de los numeros atomicos 20-29, 31-33, 37-39, 42-44, 49 o 57-83, y los radicales R2, R3, R4, U y U1 representan el significado indicado más abajo; o una cadena de carbonos con C1-30 unida con el ligador L a través de -CO-, -NR7- o un enlace directo; que puede ser lineal o ramificada, saturada o insaturada, y que está opcionalmente interrumpida por 1-10 átomos de oxígeno, 1-5 grupos -NHCO, 1-5 -CONH, 1-2 átomos de azufre, 1-5 grupos -NH o 1-2 grupos fenileno, que pueden estar opcionalmente sustituidos con 1-2 grupos -OH, 1-2 grupos -NH2, 1-2 grupos -COOH o 1-2 grupos -SO3H; y que está opcionalmente sustituida con 1-10 grupos -OH, 1-5 grupos -COOH, 1-2 grupos SO3H, 1- 5 grupos -NH2, grupos alcoxi C1-4; en donde R7 es H o alquilo C1-4; Rf es una cadena de carbonos perfluorada, lineal o ramificada, con la formula -CnF2nE, en la que E representa un átomo de fluor, cloro, bromo, yodo o hidrogeno terminal y n son los numeros 4-30; K es un complejo metálico de la formula general (2), en donde R1 es un átomo de hidrogeno o un equivalente de iones metálicos de los numeros atomicos 21-29, 31-33, 37-39, 42-44, 49 o 57-83, con la condicion de que al menos dos R1 sean equivalentes de iones metálicos; R2 y R3 representan, de modo independiente entre sí, hidrogeno, alquilo C1-7, bencilo, fenilo, -CH2OH o -CH2OCH3; y U representa -C6H4-O-CH2-omega-, -(CH2)1-5-omega, un grupo fenileno, -CH2-NHCO-CH2-CH(CH2COOH)-C6H4- omega-, -C6H4-(OCH2CH2)0-1-N(CH2COOH)-CH2-omega o un grupo alquileno C1-12 o -(CH2)7-12-C6H4-O- opcionalmente interrumpido por uno o varios átomos de oxígeno, 1 a 3 grupos -NHCO-, 1 a 3 grupos -CONH y/o sustituido con 1 a 3 grupos -(CH2)0-5COOH, en donde omega es el sitio de union con -CO-; o de la formula general (3), en donde R1 tiene el significado indicado con anterioridad, R4 representa hidrogeno o un equivalente de ion metálico mencionado en R1 y U1 representa -C6H4-O-CH2-omega- o un grupo -(CH2)p'-, en donde omega es el sitio de union con -CO- y p' es un numero entero entre 1 y 4; o de la formula general (4), en donde R1 y R2 tienen el significado mencionado con anterioridad; o de la formula general (5) o (6), en donde R1 tiene el significado indicado con anterioridad, o de la formula general (7), en donde R1 tiene el significado indicado con anterioridad, o de la formula general (8), en donde R1 y U1 tienen el significado mencionado con anterioridad en donde omega es el sitio de union con -CO- o de la formula general (9), en donde R1 tiene el significado indicado con anterioridad, y U2 representa un grupo alquileno C1-20 de cadena lineal o ramificada, saturado o insaturado, que opcionalmente contiene grupo imino, fenileno, fenilenoxi, fenilenimino, amida, hidrazida, carbonilo, éster, átomos de oxígeno, azufre y/u oxígeno, opcionalmente sustituido por grupos hidroxi, mercapto, oxo, tioxo, carboxi, carboxialquilo, éster y/o amino, y en el radical K puede haber grupos ácidos eventualmente existentes, opcionalmente como sales de bases o aminoácidos o amidas de aminoácidos orgánicos y/o inorgánicos; y L representa un radical seleccionado de los siguientes radicales de formulas (10) a (12), en donde n' y m' representan, de modo independientes entre sí, un numero entero entre 0 y 4, y m' + n' mayor o igual 1, y R8 y R8' son, de modo independiente entre sí, ya sea -H u -OH, en donde en el caso de m' + n' > 1, cada grupo -(CR8R8')- puede ser igual o diferente; y W es un enlace directo, -O- o un grupo fenileno, que puede estar opcionalmente sustituido con 1 a 4 grupos hidroxi, y q' es 1, 2, 3 o 4; en donde alfa es el sitio de union de L con el complejo K, beta es el sitio de union de L con el radical Q y gamma representa el sitio de union del L con el radical X; y X es un grupo de la formula (13), en donde Y es un enlace directo, un grupo -CO- o un grupo NR6; en donde R6 es -H o una cadena de carbonos C1-15 lineal o ramificada, saturada o insaturada que puede estar interrumpida por 1-4 átomos de O, 1-3 grupos -NHCO, 1-3grupos -CONH,, 1-2 grupos -SO2, 1,2 átomos de azufre, 1-3 grupos -NH o 1-2 grupos fenileno, que pueden estar opcionalmente sustituidos con 1-2 grupos OH, 1,2 grupos NH2, 1-2 grupos -COOH o 1-2 grupos -SO3H; y que está opcionalmente sustituida con 1-10 grupos OH, 1-5 grupos -COOH, 1-2 grupos -SO3H, 1-5 grupos NH2, 1,5 grupos alcoxi C1-4; y G es -O- o -SO2-; s y s' son, de modo independiente entre sí, 1 o 2, t es 0 o 1; y (rho) representa el sitio de union de X con L y (xi) representa el sitio de union de X con Rf.Claim 1: Complexes with perfluoroalkyl content with a linker structure with nitrogen of the general formula (1), wherein: R represents a mono- or oligosaccharide radical linked through 1-OH, in this case Q has the meaning of a selected group of. delta-CO- (CH2) n '' - epsilon; delta-NH- (CH2) n '' - epsilon; delta- (CH2) m-epsilon; where n '' is an integer of 1 and 5, and m is an integer of 1 and 6; and where delta indicates the binding site with the linker L and epsilon indicates the binding site with the radical R; or R has one of the following meanings, then Q has the meaning of a direct bond: R means a polar radical selected from: the complexes K of the general formulas (2) to V, where R1 here means a hydrogen atom or a metal ion equivalent of the atomic numbers 20-29, 31-33, 37-39, 42-44, 49 or 57-83, and the radicals R2, R3, R4, U and U1 represent the meaning indicated below; or a carbon chain with C1-30 attached to linker L through -CO-, -NR7- or a direct link; which can be linear or branched, saturated or unsaturated, and which is optionally interrupted by 1-10 oxygen atoms, 1-5 -NHCO groups, 1-5 -CONH, 1-2 sulfur atoms, 1-5 -NH groups or 1-2 phenylene groups, which may be optionally substituted with 1-2 -OH groups, 1-2 -NH2 groups, 1-2 -COOH groups or 1-2 -SO3H groups; and which is optionally substituted with 1-10 -OH groups, 1-5 -COOH groups, 1-2 SO3H groups, 1- 5 -NH2 groups, C1-4 alkoxy groups; wherein R7 is H or C1-4 alkyl; Rf is a perfluorinated, linear or branched carbon chain, with the formula -CnF2nE, in which E represents a fluorine, chlorine, bromine, iodine or terminal hydrogen atom and n are numbers 4-30; K is a metal complex of the general formula (2), wherein R1 is a hydrogen atom or a metal ion equivalent of the atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57 -83, with the proviso that at least two R1s are equivalent to metal ions; R2 and R3 independently represent each other, hydrogen, C1-7 alkyl, benzyl, phenyl, -CH2OH or -CH2OCH3; and U represents -C6H4-O-CH2-omega-, - (CH2) 1-5-omega, a phenylene group, -CH2-NHCO-CH2-CH (CH2COOH) -C6H4- omega-, -C6H4- (OCH2CH2) 0-1-N (CH2COOH) -CH2-omega or a C1-12 alkylene group or - (CH2) 7-12-C6H4-O- optionally interrupted by one or more oxygen atoms, 1 to 3 -NHCO- groups, 1 to 3 groups -CONH and / or substituted with 1 to 3 groups - (CH2) 0-5COOH, where omega is the site of union with -CO-; or of the general formula (3), wherein R1 has the meaning indicated above, R4 represents hydrogen or a metal ion equivalent mentioned in R1 and U1 represents -C6H4-O-CH2-omega- or a group - (CH2) p'-, where omega is the site of union with -CO- and p 'is an integer between 1 and 4; or of the general formula (4), wherein R1 and R2 have the meaning mentioned above; or of the general formula (5) or (6), where R1 has the meaning indicated above, or of the general formula (7), where R1 has the meaning indicated above, or of the general formula (8) , where R1 and U1 have the aforementioned meaning where omega is the site of union with -CO- or of the general formula (9), where R1 has the meaning indicated above, and U2 represents a C1 alkylene group -20 straight or branched chain, saturated or unsaturated, which optionally contains imino, phenylene, phenyloxy, phenyleneimino, amide, hydrazide, carbonyl, ester, oxygen atoms, sulfur and / or oxygen groups, optionally substituted by hydroxy, mercapto groups, oxo, thioxo, carboxy, carboxy alkyl, ester and / or amino, and in the radical K there may be optionally existing acid groups, optionally as salts of bases or amino acids or amides of organic and / or inorganic amino acids; and L represents a radical selected from the following radicals of formulas (10) to (12), where n 'and m' represent, independently of each other, an integer between 0 and 4, and m '+ n' greater than or equal to 1, and R8 and R8 'are, independently of each other, either -H or -OH, where in the case of m' + n '> 1, each group - (CR8R8') - can be the same or different ; and W is a direct bond, -O- or a phenylene group, which may be optionally substituted with 1 to 4 hydroxy groups, and q 'is 1, 2, 3 or 4; where alpha is the site of union of L with the complex K, beta is the site of union of L with the radical Q and gamma represents the site of union of L with the radical X; and X is a group of the formula (13), wherein Y is a direct link, a group -CO- or an NR6 group; wherein R6 is -H or a linear or branched, saturated or unsaturated C1-15 carbon chain that may be interrupted by 1-4 O atoms, 1-3 -NHCO groups, 1-3 -CONH groups, 1-2 -SO2 groups, 1.2 sulfur atoms, 1-3 -NH groups or 1-2 phenylene groups, which may be optionally substituted with 1-2 OH groups, 1.2 NH2 groups, 1-2 -COOH groups or 1 -2 groups -SO3H; and which is optionally substituted with 1-10 OH groups, 1-5 -COOH groups, 1-2 -SO3H groups, 1-5 NH2 groups, 1.5 C1-4 alkoxy groups; and G is -O- or -SO2-; s and s' are, independently of each other, 1 or 2, t is 0 or 1; and (rho) represents the site of union of X with L and (xi) represents the site of union of X with Rf.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005033902A DE102005033902B3 (en) | 2005-07-15 | 2005-07-15 | Perfluoroalkyl-containing complexes, processes for their preparation, and their use and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054865A1 true AR054865A1 (en) | 2007-07-25 |
Family
ID=37057146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103020A AR054865A1 (en) | 2005-07-15 | 2006-07-14 | METAL COMPLEXES WITH CONTENT OF PERFLUOROALQUILO, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1904463A2 (en) |
JP (1) | JP2009501174A (en) |
KR (1) | KR20080043762A (en) |
CN (1) | CN101223148A (en) |
AR (1) | AR054865A1 (en) |
AU (1) | AU2006272025A1 (en) |
BR (1) | BRPI0613407A2 (en) |
CA (1) | CA2615443A1 (en) |
CR (1) | CR9645A (en) |
DE (1) | DE102005033902B3 (en) |
DO (1) | DOP2006000167A (en) |
EC (1) | ECSP088100A (en) |
GT (1) | GT200600313A (en) |
IL (1) | IL187926A0 (en) |
NO (1) | NO20080813L (en) |
PE (1) | PE20070376A1 (en) |
RU (1) | RU2008105356A (en) |
TN (1) | TNSN08016A1 (en) |
TW (1) | TW200706538A (en) |
UY (1) | UY29664A1 (en) |
WO (1) | WO2007009638A2 (en) |
ZA (1) | ZA200801523B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007015598A1 (en) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Use of fluorochemical compounds for diagnostic purposes using imaging techniques |
MX2010007501A (en) | 2008-01-08 | 2010-08-16 | Lantheus Medical Imaging Inc | N-alkoxyamide conjugates as imaging agents. |
US20210101905A1 (en) * | 2019-10-04 | 2021-04-08 | Llnited States Government as represented by the Department of Veterans Affairs | Development of Imaging and Therapeutic Glucose Analogues for Sodium Dependent Glucose Transporters |
EP4059925A1 (en) | 2021-03-15 | 2022-09-21 | Bayer Aktiengesellschaft | New contrast agent for use in magnetic resonance imaging |
CN114181164A (en) * | 2021-12-13 | 2022-03-15 | 武汉大学中南医院 | Synthesis method and application of MRI contrast agent based on Fe (II) specificity |
EP4335840A1 (en) | 2022-09-09 | 2024-03-13 | Bayer Aktiengesellschaft | New contrast agents for use in diagnostic imaging |
EP4335462A1 (en) | 2022-09-09 | 2024-03-13 | Bayer AG | Contrast agents for use in diagnostic computed tomography imaging |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4317588C2 (en) * | 1993-05-24 | 1998-04-16 | Schering Ag | Macrocyclic metal complexes containing fluorine, process for their preparation and their use |
DE19603033A1 (en) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics |
DE19744003B4 (en) * | 1997-09-26 | 2004-07-08 | Schering Ag | Contrast agent for infarct and necrosis imaging |
DE19744004C1 (en) * | 1997-09-26 | 1999-07-22 | Schering Ag | Lipophilic metal complexes for necrosis and infarct imaging |
DE19914101C1 (en) * | 1999-03-22 | 2000-10-12 | Schering Ag | Perfluoroalkylamides, their preparation and their use in diagnostics |
DE10040858C2 (en) * | 2000-08-11 | 2003-12-18 | Schering Ag | Perfluoroalkyl-containing complexes with polar residues, process for their preparation and their use |
-
2005
- 2005-07-15 DE DE102005033902A patent/DE102005033902B3/en not_active Expired - Fee Related
-
2006
- 2006-07-11 EP EP06791535A patent/EP1904463A2/en not_active Withdrawn
- 2006-07-11 CA CA002615443A patent/CA2615443A1/en not_active Abandoned
- 2006-07-11 KR KR1020087001084A patent/KR20080043762A/en not_active Application Discontinuation
- 2006-07-11 RU RU2008105356/04A patent/RU2008105356A/en not_active Application Discontinuation
- 2006-07-11 JP JP2008520780A patent/JP2009501174A/en not_active Withdrawn
- 2006-07-11 AU AU2006272025A patent/AU2006272025A1/en not_active Abandoned
- 2006-07-11 WO PCT/EP2006/006777 patent/WO2007009638A2/en active Application Filing
- 2006-07-11 UY UY29664A patent/UY29664A1/en not_active Application Discontinuation
- 2006-07-11 BR BRPI0613407-6A patent/BRPI0613407A2/en not_active Application Discontinuation
- 2006-07-11 CN CNA2006800258905A patent/CN101223148A/en active Pending
- 2006-07-13 DO DO2006000167A patent/DOP2006000167A/en unknown
- 2006-07-14 GT GT200600313A patent/GT200600313A/en unknown
- 2006-07-14 PE PE2006000844A patent/PE20070376A1/en not_active Application Discontinuation
- 2006-07-14 AR ARP060103020A patent/AR054865A1/en unknown
- 2006-07-14 TW TW095125755A patent/TW200706538A/en unknown
-
2007
- 2007-12-06 IL IL187926A patent/IL187926A0/en unknown
-
2008
- 2008-01-08 CR CR9645A patent/CR9645A/en unknown
- 2008-01-11 EC EC2008008100A patent/ECSP088100A/en unknown
- 2008-01-14 TN TNP2008000016A patent/TNSN08016A1/en unknown
- 2008-02-14 ZA ZA200801523A patent/ZA200801523B/en unknown
- 2008-02-14 NO NO20080813A patent/NO20080813L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007009638A2 (en) | 2007-01-25 |
WO2007009638A3 (en) | 2007-04-26 |
AU2006272025A1 (en) | 2007-01-25 |
RU2008105356A (en) | 2009-08-20 |
ZA200801523B (en) | 2008-11-26 |
CA2615443A1 (en) | 2007-01-25 |
JP2009501174A (en) | 2009-01-15 |
NO20080813L (en) | 2008-04-09 |
DOP2006000167A (en) | 2007-02-28 |
CN101223148A (en) | 2008-07-16 |
IL187926A0 (en) | 2008-03-20 |
BRPI0613407A2 (en) | 2011-01-11 |
DE102005033902B3 (en) | 2007-04-05 |
CR9645A (en) | 2008-05-21 |
TW200706538A (en) | 2007-02-16 |
GT200600313A (en) | 2007-04-23 |
TNSN08016A1 (en) | 2009-07-14 |
ECSP088100A (en) | 2008-05-30 |
KR20080043762A (en) | 2008-05-19 |
EP1904463A2 (en) | 2008-04-02 |
PE20070376A1 (en) | 2007-04-20 |
UY29664A1 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054865A1 (en) | METAL COMPLEXES WITH CONTENT OF PERFLUOROALQUILO, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE | |
AR057579A1 (en) | SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC) | |
ES2620379T3 (en) | Quinoline and quinoxaline amides as sodium channel modulators | |
CY1117113T1 (en) | SERIES HCV PROTECTION SUSPENSIONS MADE BY Macrocyclic Proline | |
AR057034A1 (en) | METHODS TO PURIFY TIGECICLINE | |
AR044561A1 (en) | STATIN DERIVATIVES | |
AR078634A1 (en) | PROCEDURE FOR THE PREPARATION OF A PROGRESSIVE PHOTO-PROTECTOR SILICON ORGANIC POLYMER; POLYMER OBTAINED; ITS USE FOR THE PREPARATION OF COMPOSITIONS AND AS A PHOTOCHEMICAL PRECURSOR OF UV ABSORBENTS; COSMETIC OR DERMATOLOGICAL COMPOSITION THAT INCLUDES SUCH POLYMER; PROCEEDING FOR | |
PE20120374A1 (en) | FENYLUREAS AND PHENYLAMIDES AS VANYLLOID RECEPTOR LIGANDS | |
ES2683860T3 (en) | Novel succinate compounds with cell permeability | |
NI201100219A (en) | NEW CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. | |
AR036183A1 (en) | 1,4,7,10-TETRAAZACICLODODAN, A PROCEDURE FOR PREPARATION AND USE FOR THE PREPARATION OF A CONJUGATE WITH A BIOMOLECULA | |
EA201170130A1 (en) | BENZOXASASES, BENZOTHIAZINES AND RELATED COMPOUNDS THAT HAVE INHIBITING NOS ACTIVITY | |
AR075673A1 (en) | PIRIDAZINONAS REPLACED WITH PHENYL IN POSITION 4, ITS USE AS HERBICIDES AND INSECTICIDES IN COMPOSITIONS AND METHODS OF COMBAT OF INDESATED PLANTS THAT INCLUDE THEM | |
AR082995A1 (en) | PROFARMACES UNDERSTANDING AN EXENDINE CONNECTOR CONJUGATE | |
AR092538A1 (en) | TRICICLIC SUNFLOW INHIBITORS | |
AR061858A1 (en) | HETEROCICLICAL COMPOSTS OF PHOSPHONATES AND PHOSPHINATES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTIDIABETIC AGENTS. | |
AR082112A1 (en) | DERIVATIVES OF IMIDAZOPIRIDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS | |
AR091381A1 (en) | NEPRILISINE INHIBITORS | |
AR054341A1 (en) | SYNERGIC COMBINATIONS OF FUNGICIDAL ACTIVE COMPOUNDS | |
AR057414A1 (en) | PROSTAGLANDINA DERIVATIVES | |
AR080540A1 (en) | SALTS OF N-PHOSPHONOMETIL GLICINA AND DERIVATIVES OF GUANIDINE AND A HERBICIDE COMPOSITION | |
CO6230990A2 (en) | NEW TRICYCLE DERIVATIVES ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CO6450684A2 (en) | AMIDA DERIVATIVE | |
AR069643A1 (en) | DIAZENIDIOLATE DERIVATIVES, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
JP2012514622A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |